413 related articles for article (PubMed ID: 32092903)
41. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
42. P2y12 Receptor Promotes Pressure Overload-Induced Cardiac Remodeling via Platelet-Driven Inflammation in Mice.
Wu L; Zhao F; Dai M; Li H; Chen C; Nie J; Wang P; Wang DW
Hypertension; 2017 Oct; 70(4):759-769. PubMed ID: 28827474
[TBL] [Abstract][Full Text] [Related]
43. P2Y12 receptor antagonists in acute coronary syndrome: clinical implications of pharmacologic and pharmacogenetic differences.
Singh M; Adigopula S; Ahmad N; Arora R; Khosla S
Recent Pat Cardiovasc Drug Discov; 2011 Sep; 6(3):207-14. PubMed ID: 21861826
[TBL] [Abstract][Full Text] [Related]
44. P
Siegel PM; Sander L; Fricke A; Stamm J; Wang X; Sharma P; Bassler N; Ying YL; Olivier CB; Eisenhardt SU; Bode C; Ahrens I; Diehl P; Peter K
Sci Rep; 2021 Aug; 11(1):17459. PubMed ID: 34465804
[TBL] [Abstract][Full Text] [Related]
45. Identification of a New Morpholine Scaffold as a P2Y12 Receptor Antagonist.
Ahn YH; Lee JY; Park HD; Kim TH; Park MC; Choi G; Kim S
Molecules; 2016 Aug; 21(9):. PubMed ID: 27563870
[TBL] [Abstract][Full Text] [Related]
46. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
[TBL] [Abstract][Full Text] [Related]
47. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Björkman JA; Zachrisson H; Forsberg GB; von Bahr H; Hansson GI; Warner TD; Nylander S
Thromb Res; 2013 Apr; 131(4):313-9. PubMed ID: 23419412
[TBL] [Abstract][Full Text] [Related]
48. Comparison of four methods to assess high-on platelet reactivity under P2Y12 receptor inhibitor.
Mingant F; Didier R; Gilard M; Martin F; Nicol PP; Ugo V; Lippert E; Galinat H
Platelets; 2018 May; 29(3):257-264. PubMed ID: 29580115
[TBL] [Abstract][Full Text] [Related]
49. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
Jakubowski JA; Zhou C; Egan B; Wells M; Kotob-Yahfoufi M; Sugidachi A; Dahlen JR
Platelets; 2011; 22(8):619-25. PubMed ID: 21639823
[TBL] [Abstract][Full Text] [Related]
50. Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction.
Gasecka A; Nieuwland R; Budnik M; Dignat-George F; Eyileten C; Harrison P; Huczek Z; Kapłon-Cieślicka A; Lacroix R; Opolski G; Pluta K; van der Pol E; Postuła M; Leroyer A; Siljander P; Sturk A; Filipiak KJ
Platelets; 2020; 31(1):26-32. PubMed ID: 30585111
[TBL] [Abstract][Full Text] [Related]
51. Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered.
Cohen MV; Downey JM
J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):179-90. PubMed ID: 24298192
[TBL] [Abstract][Full Text] [Related]
52. Role of P2Y
Zhang Y; Zhang S; Ding Z
Adv Exp Med Biol; 2017; 906():307-324. PubMed ID: 27628007
[TBL] [Abstract][Full Text] [Related]
53. CalDAG-GEFI Deficiency Reduces Atherosclerotic Lesion Development in Mice.
Boulaftali Y; Owens AP; Beale A; Piatt R; Casari C; Lee RH; Conley PB; Paul DS; Mackman N; Bergmeier W
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):792-9. PubMed ID: 26988592
[TBL] [Abstract][Full Text] [Related]
54. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
55. Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y
Wolska N; Boncler M; Polak D; Wzorek J; Przygodzki T; Gapinska M; Watala C; Rozalski M
Molecules; 2019 Dec; 25(1):. PubMed ID: 31905703
[TBL] [Abstract][Full Text] [Related]
56. Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression.
Reiner MF; Akhmedov A; Stivala S; Keller S; Gaul DS; Bonetti NR; Savarese G; Glanzmann M; Zhu C; Ruf W; Yang Z; Matter CM; Lüscher TF; Camici GG; Beer JH
Cardiovasc Res; 2017 Jan; 113(1):61-69. PubMed ID: 28028070
[TBL] [Abstract][Full Text] [Related]
57. The effect of smoking on residual platelet reactivity to clopidogrel: a systematic review and meta-analysis.
Liu Z; Xiang Q; Mu G; Xie Q; Zhou S; Wang Z; Chen S; Hu K; Gong Y; Jiang J; Cui Y
Platelets; 2020; 31(1):3-14. PubMed ID: 30744477
[TBL] [Abstract][Full Text] [Related]
58. A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y
Li X; Liu P; Xu Z; Sun D; Gu J; Miao Y; Zhang J; Cao X
Cardiovasc Drugs Ther; 2020 Feb; 34(1):15-23. PubMed ID: 32062793
[TBL] [Abstract][Full Text] [Related]
59. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
60. A complementary role for tetraspanin superfamily member TSSC6 and ADP purinergic P2Y
Makkawi M; Howells D; Wright MD; Jackson DE
Thromb Res; 2018 Jan; 161():12-21. PubMed ID: 29178985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
